Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis

Retina

Volumn 33, Issue 10, 2013, Pages 2149-2154

  Taylor, Simon R J ^a,b   Banker, Alay ^c   Schlaen, Ariel ^d,e   Couto, Cristobal ^d,e   Matthe, Egbert ^f   Joshi, Lavnish ^a,g   Menezo, Victor ^a   Nguyen, Ethan ^h   Tomkins Netzer, Oren ^a   Bar, Asaf ^a   Morarji, Jiten ^a   McCluskey, Peter ^h,i   Lightman, Sue ^a,g  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Banker's Retina Clinic and Laser Centre   (India)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e UNIVERSIDAD AUSTRAL   (Argentina)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h SYDNEY EYE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CHRONIC DISEASE; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CORTICOSTEROID THERAPY; DRUG EFFICACY; EYE PAIN; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMEDIATE UVEITIS; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; MACULAR THICKNESS; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RELAPSE; REMISSION; RETINA MACULA CYSTOID EDEMA; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT DURATION; UVEITIS; VISION; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; YOUNG ADULT;

EID: 84887041749     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31828ac07d     Document Type: Article

References (38)

1. Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010;224 (suppl 1):46-53.
2. Tomkins-Netzer O, Taylor SR, Lightman S. Corticosteroidsparing agents: new treatment options. Dev Ophthalmol 2012; 51:47-56.
3. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108:1134-1139.
4. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 2002;109:1709-1716.
5. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997;115:1152-1156.
6. Hardwig PW, Pulido JS, Erie JC, et al. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006;142:883-885.
7. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116: 797-801.
8. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009; 116:2188-2198 e2181.
9. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman S. Intravitreal methotrexate in uveitis. Ophthalmology 2012;119:878-879.
10. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916 e1911-1917.
11. Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Retina 2012;32:1395-1402.
12. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516.
13. Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol 2005;139:900-905.
14. Djalilian AR, Nussenblatt RB. Immunosuppression in uveitis. Ophthalmol Clin North Am 2002;15:395-404, viii.
15. Velez G, Boldt HC, Whitcup SM, et al. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers 2002;33:329-333.
16. Jeffes EW III, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995;104:183-188.
17. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-682.
18. Lukashev D, Ohta A, Apasov S, et al. Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol 2004;173:21-24.
19. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-2682.
20. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-273.
21. Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994;153:4159-4168.
22. Constantin A, Loubet-Lescoulie P, Lambert N, et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 1998;41:48-57.
23. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 1996;270(2 Pt 1):C522-C529.
24. Li Y, Jiang L, Zhang S, et al. Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Rheumatol Int 2012;32: 2415-2422.
25. Yu CR, Oh HM, Golestaneh N, et al. Persistence of IL-2 expressing Th17 cells in healthy humans and experimental autoimmune uveitis. Eur J Immunol 2011;41:3495-3505.
26. Henson JW, Yang J, Batchelor T. Intraocular methotrexate level after high-dose intravenous infusion. J Clin Oncol 1999;17:1329.
27. de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 1999;83:448-451.
28. Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term followup of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 2002;109:370-377.
29. Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010; 117:356-365.
30. Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149: 423-432 e421-422.
31. Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117: 576-584.
32. Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009;60:1540-1547.
33. Joshi L, Taylor SR, Salama A, et al. Rituximab in refractory ophthalmicWegener's granulomatosis: PR3 titers predict relapse, but repeat treatment is effective. ARVO Meeting Abstracts. April 22, 2011 2011;52(6):4252.
34. Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480.
35. Fine BS, Brucker AJ. Macular edema and cystoid macular edema. Am J Ophthalmol 1981;92:466-481.
36. Newsom WA, Hood CI, Horwitz JA, et al. Cystoid macular edema: histopathologic and angiographic correlations. A clinicopathologic case report. Trans Am Acad Ophthalmol Otolaryngol 1972;76:1005-1009.
37. Taylor SR, Lightman SL, Sugar EA, et al. The impact of macular edema on visual function in intermediate, posterior, and Panuveitis. Ocul Immunol Inflamm 2012;20:171-181.
38. de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30:452-470.